Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Ver­tex Phar­ma­ceu­ti­cals an­nounced Fri­day af­ter­noon that it won’t move for­ward with its type 1 di­a­betes cell ther­a­py that’s de­liv­ered in a … ...

Over the past decade, several dozen cell and gene therapies have reached market in the U.S., bringing with them the promise of long-lasting benefits for serious diseases. Peter Marks’ fingerprints are ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 study and ...

VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of thePhase 1/2 VX-264 (cells + device) study and the planned analysis at Day 90 for Part B. In Part B of the study ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories like pain management with its non-opioid drug Journavx. The FDA greenlit ...

In this episode, Barry chats with Vertex Minerals (ASX:VTX) executive chairman Roger Jackson, who is now making that pivotal switch to production from the Reward gold mine in the firing Lachlan ...

The forward-looking statements contained in this Press Release are based on the expectations, estimates and projections of management of Vertex as of the date of this Press Release unless ...

Vertex Trading Down 1.2 % NASDAQ VERX opened at $35.71 on Monday. The company has a debt-to-equity ratio of 1.29, a quick ratio of 1.04 and a current ratio of 1.04. Vertex, Inc. has a one year low ...